ALNYLAM PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Additional Paid in Capital, Common Stock of $7.72 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-30
- 2026-06-30: Additional Paid in Capital, Common Stock $7.72B.
- 2025-12-31: Additional Paid in Capital, Common Stock $7.51B.
- 2025-09-30: Additional Paid in Capital, Common Stock $7.41B.
- 2025-06-30: Additional Paid in Capital, Common Stock $7.69B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $7.72B 10-Q · filed 2026-07-30 |
| 2025-12-31 | $7.51B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $7.41B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $7.69B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $7.50B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $7.39B 10-K · filed 2026-02-12 |
| 2024-09-30 | $7.26B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $7.12B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $6.88B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $6.81B 10-K · filed 2025-02-13 |
| 2023-09-30 | $6.74B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $6.65B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $6.52B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.45B 10-K · filed 2024-02-15 |
| 2022-09-30 | $6.34B 10-Q · filed 2022-10-27 |
| 2022-06-30 | $6.17B 10-Q · filed 2022-07-28 |
| 2022-03-31 | $6.12B 10-Q · filed 2022-04-28 |
| 2021-12-31 | $6.06B 10-K · filed 2023-02-23 |
| 2021-09-30 | $5.97B 10-Q · filed 2021-10-28 |
| 2021-06-30 | $5.86B 10-Q · filed 2021-08-03 |
| 2021-03-31 | $5.75B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $5.64B 10-K · filed 2022-02-10 |
| 2020-09-30 | $5.59B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.52B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.29B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.20B 10-K · filed 2021-02-11 |
| 2019-09-30 | $5.09B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $5.03B 10-Q · filed 2019-08-06 |
| 2019-03-31 | $4.60B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $4.18B 10-K · filed 2020-02-13 |
| 2018-09-30 | $4.14B 10-Q · filed 2018-11-07 |
| 2018-06-30 | $4.04B 10-Q · filed 2018-08-02 |
| 2018-03-31 | $4.01B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $3.95B 10-K · filed 2019-02-14 |
| 2017-09-30 | $3.10B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $3.04B 10-Q · filed 2017-08-09 |
| 2017-03-31 | $2.63B 10-Q · filed 2017-05-05 |
| 2016-12-31 | $2.61B 10-K · filed 2018-02-15 |
| 2016-09-30 | $2.59B 10-Q · filed 2016-11-03 |
| 2016-06-30 | $2.57B 10-Q · filed 2016-08-04 |
| 2016-03-31 | $2.55B 10-Q · filed 2016-05-04 |
| 2015-12-31 | $2.51B 10-K · filed 2017-02-15 |
| 2015-09-30 | $2.48B 10-Q · filed 2015-11-09 |
| 2015-06-30 | $2.47B 10-Q · filed 2015-08-07 |
| 2015-03-31 | $2.45B 10-Q · filed 2015-05-08 |
| 2014-12-31 | $1.84B 10-K · filed 2016-02-12 |
| 2014-09-30 | $1.82B 10-Q · filed 2014-11-06 |
| 2014-06-30 | $1.81B 10-Q · filed 2014-08-08 |
| 2014-03-31 | $1.78B 10-Q · filed 2014-05-09 |
| 2013-12-31 | $846.23M 10-K · filed 2015-02-13 |
| 2013-09-30 | $833.66M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $813.61M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $806.14M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $624.88M 10-K · filed 2014-02-20 |
| 2012-09-30 | $621.35M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $613.15M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $609.26M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $518.73M 10-K · filed 2013-02-19 |
| 2011-09-30 | $514.29M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $509.83M 10-Q · filed 2011-08-03 |
| 2011-03-31 | $504.79M 10-Q · filed 2011-05-05 |
| 2010-12-31 | $500.44M 10-K · filed 2012-02-13 |
| 2010-09-30 | $495.35M 10-Q · filed 2010-11-04 |
| 2010-06-30 | $490.56M 10-Q · filed 2010-08-05 |
| 2009-12-31 | $476.66M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |